11. July 2017
Transglutaminase-Newsletter | July 2017
ZediXclusive TG6-ab ELISA kits E103 and E104: Revised versions of ELISA kits E003 and E004.
Improvements:
Read more!
Get your serum sample measured for TG6 autoantibodies!
In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.
Link to Order Sheet (English)
Link to Order Sheet (German)
ELISA for detection of TG6 autoantibodies
Transglutaminase-Newsletter | July 2017
ZediXclusive TG6-ab ELISA kits E103 and E104: Revised versions of ELISA kits E003 and E004.
Improvements:
- Background subtraction not necessary anymore.
Therefore, now you can measure up to 40 sera in duplicates with one kit (96 wells). - The calibrators are adapted, so that the more relevant lower titers are covered.
Titers (U/mL) obtained by the new E103/E104 kits can be translated to titers of old kit versions E003/E004 and vice versa! - Cutoffs are redefined based on a sera collective of 86 patients with various neurological disorders, and 38 blood donors, equally distributed by sex and age.
Read more!
Get your serum sample measured for TG6 autoantibodies!
In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.
Link to Order Sheet (English)
Link to Order Sheet (German)
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Zedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
Artikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
Preview: Catalogue Editorial 2019
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering
Tridegin as FXIIIa inhibitor
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia